Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S (Dr Reddys Laboratories Australia Pty Ltd)
Product name
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S
Date registered
Evaluation commenced
Decision date
Approval time
150 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE-REDDY'S, TERIFLUNOMIDE-DRLA, TERIFLUNOMIDE-RZ, TERIFLUNOMIDE-DR.REDDY'S (tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.